NCT06900647

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Phase I Study to Evaluate the Safety and Preliminary Efficacy of Bortezomib Combined With Cisplatin in Patients With Recurrent or Metastatic Breast Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.

Conditions

• Metastatic Breast Cancer
• Recurrent Breast Cancer

Interventions

Type	Name	Description
DRUG	Bortezomib (B)	1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
DRUG	Cisplatin (CDDP)	50mg/m2, IV, D1-3, every 3 weeks
DRUG	Bortezomib (B)	1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
DRUG	Bortezomib (B)	1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
DRUG	Cisplatin (CDDP)	70mg/m2, IV, D1-3, every 3 weeks

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-06-30
• Completion: 2028-06-30
• First posted: 2025-03-28
• Last updated: 2025-04-02

Locations

1 site across 1 country: China